ALXN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This is the expense the company spent on research and development. Alexion Pharmaceuticals, Inc.'s research and development for the three months ended in Dec. 2013 was $86 Mil. Its research and development for the trailing twelve months (TTM) ended in Dec. 2013 was $317 Mil.
This is the expense the company spent on research and development.
Alexion Pharmaceuticals, Inc. Research & Development for the trailing twelve months (TTM) ended in Dec. 2013 was 74.536 (Mar. 2013 ) + 68.563 (Jun. 2013 ) + 88.209 (Sep. 2013 ) + 85.785 (Dec. 2013 ) = $317 Mil.
* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.
If competitive advantage is created by a patent or tech advantage, at some point it will disappear.
High R&D usually dictates high SG&A which threatens the competitive advantage.
Alexion Pharmaceuticals, Inc. Annual Data
|Research & Development||60||91||83||69||63||82||98||137||223||317|
Alexion Pharmaceuticals, Inc. Quarterly Data
|Research & Development||37||34||45||60||54||63||75||69||88||86|